DK1069185T3 - Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof - Google Patents

Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof

Info

Publication number
DK1069185T3
DK1069185T3 DK99912098.3T DK99912098T DK1069185T3 DK 1069185 T3 DK1069185 T3 DK 1069185T3 DK 99912098 T DK99912098 T DK 99912098T DK 1069185 T3 DK1069185 T3 DK 1069185T3
Authority
DK
Denmark
Prior art keywords
chain
humanized antibody
region
humanized
antibody
Prior art date
Application number
DK99912098.3T
Other languages
English (en)
Inventor
Koh Chugai Sato
Hideki Adachi
Naohiro Yabuta
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1069185T3 publication Critical patent/DK1069185T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99912098.3T 1998-04-03 1999-04-02 Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof DK1069185T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9185098 1998-04-03
PCT/JP1999/001768 WO1999051743A1 (fr) 1998-04-03 1999-04-02 Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises

Publications (1)

Publication Number Publication Date
DK1069185T3 true DK1069185T3 (da) 2011-06-27

Family

ID=14038058

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99912098.3T DK1069185T3 (da) 1998-04-03 1999-04-02 Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof

Country Status (19)

Country Link
US (2) US6677436B1 (da)
EP (2) EP1069185B1 (da)
JP (2) JP3998419B2 (da)
KR (1) KR20010042435A (da)
CN (1) CN1303431A (da)
AT (1) ATE512225T1 (da)
AU (1) AU752730B2 (da)
BR (1) BR9909382A (da)
CA (1) CA2325346A1 (da)
DK (1) DK1069185T3 (da)
ES (1) ES2364266T3 (da)
HU (1) HUP0101160A2 (da)
IL (1) IL138801A0 (da)
NO (1) NO20004946L (da)
PL (1) PL343322A1 (da)
PT (1) PT1069185E (da)
SK (1) SK14812000A3 (da)
TR (2) TR200101541T2 (da)
WO (1) WO1999051743A1 (da)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4423680B2 (ja) 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
US6703197B1 (en) * 1996-11-27 2004-03-09 Martinex R&D, Inc. Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
EP1222854B1 (en) * 1999-10-01 2011-02-16 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
DE60229961D1 (de) * 2001-08-29 2009-01-02 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
CA2460917A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
MXPA04010851A (es) * 2002-05-01 2005-02-14 Schering Ag Proteinas de fusion de trombomodulina dirigidas al factor tisular novedoso como anticoagulantes.
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
WO2003099324A1 (fr) * 2002-05-23 2003-12-04 Chugai Seiyaku Kabushiki Kaisha Agent neutralisant l'inhibiteur du facteur tissulaire et agent neutralisant la preparation du facteur viii active de coagulation sanguine
WO2004019966A1 (ja) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
CA2515081A1 (en) * 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US8765124B2 (en) * 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
KR20060035608A (ko) * 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
EP1667718A4 (en) * 2003-08-29 2007-05-02 Centocor Inc METHOD FOR STIMULATING THE SURVIVAL OF A GRAFT WITH ANTI-TISSUE FACTOR ANTIBODY
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CA2544865C (en) * 2003-11-05 2019-07-09 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
CN101146909A (zh) * 2005-03-25 2008-03-19 格黎卡特生物技术股份公司 针对MCSP的并且具有增加的Fc受体结合亲和性和效应子功能的抗原结合分子
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
PL1876236T3 (pl) 2005-04-08 2015-01-30 Chugai Pharmaceutical Co Ltd Przeciwciała zastępujące czynność czynnika krzepnięcia VIII
BRPI0611445A2 (pt) * 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
US8124076B2 (en) 2005-08-18 2012-02-28 Ramot At Tel Aviv University Ltd. Single chain antibodies against β-amyloid peptide
RU2482132C2 (ru) * 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
DK2009101T3 (da) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antistofmodifikationsfremgangsmåde til oprensning af et bispecifikt antistof
US11046784B2 (en) * 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
ES2699273T3 (es) 2006-12-01 2019-02-08 Novartis Ag Anticuerpos anti-P-selectina y métodos de uso de los mismos para tratar enfermedades inflamatorias
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
DK2236604T3 (da) 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd Anti-NR10 antistof og anvendelse deraf
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SI3031825T1 (sl) * 2008-03-14 2019-12-31 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
JP5573156B2 (ja) 2008-07-10 2014-08-20 東レ株式会社 癌の治療及び予防用医薬組成物
KR101667319B1 (ko) 2008-08-05 2016-10-18 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
BRPI0921586A2 (pt) * 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CN101717447B (zh) * 2009-12-17 2012-06-27 山西省生物研究所 一种抗人重组组织因子单克隆抗体的制备方法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011096519A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
DK2532364T3 (da) 2010-02-04 2016-08-15 Toray Industries Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft
RU2597971C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP5742714B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
AU2011267106B2 (en) 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
JP6065590B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014004828B8 (pt) 2011-09-01 2022-03-29 Chugai Pharmaceutical Co Ltd Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
PL2818482T3 (pl) 2012-02-21 2019-11-29 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
IN2014KN01716A (da) 2012-02-21 2015-10-23 Toray Industries
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
CN104203281B (zh) 2012-03-30 2019-07-26 东丽株式会社 胆囊癌的治疗和/或预防用药物组合物
EP2832365B1 (en) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
KR102312856B1 (ko) 2012-08-24 2021-10-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
JP6284481B2 (ja) 2012-09-28 2018-02-28 中外製薬株式会社 血液凝固反応の評価方法
TR201819812T4 (tr) 2013-08-09 2019-01-21 Toray Industries Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
US10538591B2 (en) 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
WO2016027859A1 (ja) 2014-08-20 2016-02-25 中外製薬株式会社 蛋白質溶液の粘度測定方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
WO2016098356A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
KR20180095740A (ko) 2015-02-27 2018-08-27 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2016248817A1 (en) 2015-04-17 2017-08-17 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC MEDICINE INDUCING CELLULAR INJURY FOR USE IN THE TREATMENT OF CANCER
WO2017170334A1 (ja) 2016-03-28 2017-10-05 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
MX2019004779A (es) 2016-10-28 2019-08-12 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
US20210107994A1 (en) 2017-03-31 2021-04-15 Public University Corporation Nara Medical University Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
MX2020005473A (es) * 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
SG11202006400UA (en) 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CA3095719A1 (en) 2018-03-30 2019-10-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JPWO2019225568A1 (ja) 2018-05-21 2021-07-01 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha FILLING NOZZLE
KR20210154179A (ko) 2019-04-18 2021-12-20 에이씨 이뮨 에스.에이. 치료 및 진단용 신규한 분자
CN115151562A (zh) 2019-12-04 2022-10-04 Ac免疫有限公司 用于治疗和诊断的新分子
JPWO2021182572A1 (da) 2020-03-12 2021-09-16
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
EP4119157A4 (en) 2020-03-12 2024-03-27 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
BR112022018157A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US20230174670A1 (en) 2020-05-14 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
EP4155405A1 (en) 2020-05-22 2023-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
WO2022129609A2 (en) 2020-12-18 2022-06-23 Ac Immune Sa Antibody delivery
EP4360648A1 (en) 2021-06-23 2024-05-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240024803A (ko) 2021-06-23 2024-02-26 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2023008462A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
CA3227698A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022316644A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2023033129A1 (da) 2021-09-03 2023-03-09
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JP4423680B2 (ja) * 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用

Also Published As

Publication number Publication date
EP1069185A4 (en) 2005-01-19
PT1069185E (pt) 2011-08-11
PL343322A1 (en) 2001-08-13
EP2363484A3 (en) 2012-04-25
CA2325346A1 (en) 1999-10-14
JP3998419B2 (ja) 2007-10-24
US20040044187A1 (en) 2004-03-04
WO1999051743A1 (fr) 1999-10-14
HUP0101160A2 (hu) 2001-08-28
NO20004946L (no) 2000-12-04
SK14812000A3 (sk) 2001-08-06
CN1303431A (zh) 2001-07-11
TR200002885T2 (tr) 2000-12-21
ES2364266T3 (es) 2011-08-30
IL138801A0 (en) 2001-10-31
EP1069185A1 (en) 2001-01-17
JP2008161198A (ja) 2008-07-17
ATE512225T1 (de) 2011-06-15
KR20010042435A (ko) 2001-05-25
JP4180106B2 (ja) 2008-11-12
AU3055699A (en) 1999-10-25
US6677436B1 (en) 2004-01-13
NO20004946D0 (no) 2000-10-02
BR9909382A (pt) 2000-12-05
US7494647B2 (en) 2009-02-24
AU752730B2 (en) 2002-09-26
EP1069185B1 (en) 2011-06-08
EP2363484A2 (en) 2011-09-07
TR200101541T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
DK1069185T3 (da) Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
NO20001671L (no) Naturlige humaniserte antistoff
EP0770628A4 (en) HUMAN ANTIBODIES RECONSTITUTED AGAINST HUMAN INTERLEUKIN-8
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
DE69633973D1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
CY1112365T1 (el) Εξανθρωπισμος του μυοειδους αντισωματος
EA200200503A1 (ru) Способ лечения ревматоидного артрита
FR2565677B1 (fr) Lithium enrobe, procede d'enrobage de lithium metallique et source d'energie utilisant du lithium enrobe.
EA199700196A1 (ru) Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом
NO913078L (no) Oekt proteinproduksjon i dyr.
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
EA199800535A1 (ru) Способ лечения боли
ATE309371T1 (de) Protein mit dnase-aktivität
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
ZA964889B (en) A method for promoting enzyme diversity
DE3262592D1 (en) Guanidinopyrimidines
JPS542639A (en) Coding method